Blood Editors Announce Top 10 Manuscripts of 2018
Published on: December 20, 2018
December 20, 2018) – The editors of Blood,
the most-cited journal in hematology, have selected the top manuscripts of 2018.
10 publications were chosen from the rich variety of top studies that appeared
in the journal in 2018,” said Blood Editor-in-Chief
Bob Löwenberg, MD, PhD. “These articles offer a representative sampling of the
notable advances of scientific and clinical knowledge in virtually every domain
in the field of hematology.”
following manuscripts were selected by Dr. Löwenberg and Blood Deputy Editor Nancy Berliner. The editors’ also provided
comments on each study:
minimal residual disease in adults with B-cell precursor acute lymphoblastic
leukemia, Gökbuget et al.
study reports high rates of response (78%) and prolonged survival with
blinatumomab immunotherapy for adults with minimal residual disease–positive
precursor B-cell acute lymphoblastic leukemia.
chimeric antigen receptor T cells are active against B- and T-cell lymphomas, Scarfò
These preclinical studies support the use of CD37 as
a target antigen for novel chimeric antigen receptor T-cell reagents. They
demonstrate activity against B- and T-cell lymphomas both by single-antigen
targeting and by dual-specific therapy in combination with anti-CD19.
tumor DNA reveals genetics, clonal evolution, and residual disease in classical
Hodgkin lymphoma, Spina et al.
mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma, Tiacci et al
two papers elucidate the molecular landscape of classical Hodgkin lymphoma
(cHL). The first study demonstrates that circulating tumor DNA (ctDNA) can be
used to assess the genetics of cHL and to track residual disease. The second
study uses microdissection and single-cell sequencing to establish the
importance of JAK-STAT pathway genes in cHL, an observation that is mirrored in
the ctDNA study.
spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase
Deficiency Natural History Study, Grace
This retrospective study of 254 patients provides a
comprehensive overview of the clinical spectrum of pyruvate kinase deficiency
(PKD) and elucidates the broad range of the clinical severity of PKD and
characterizes the complex genotype-phenotype relationship of the disease.
phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat
relapse after transplantation, Romee et al.
The authors report the results of the first-in-human
clinical trial of a novel interleukin-15 (IL-15) fusion protein to promote
graft-versus-leukemia without enhancing graft-versus-host disease in patients
with hematologic malignancies who relapsed after allogeneic stem cell
tyrosine kinase inhibitors selectively block atherosclerotic
plaque–triggered thrombus formation in humans, Busygina et al.
These investigations demonstrate that ibrutinib
selectively and irreversibly inhibits platelet aggregation on atherosclerotic
plaques, suggesting a novel use of low-dose Bruton tyrosine kinase inhibitors
in the prevention of progression of atherosclerosis.
immunoglobulin vs observation in childhood immune thrombocytopenia: a
randomized controlled trial, Heitink-Pollé et al.
This paper presents the long-awaited results of the
randomized, controlled trial comparing intravenous immunoglobulin with
observation in children with immune thrombocytopenia (ITP) at diagnosis, and it
reports the frequency of chronic ITP in treated and untreated children.
PPM1D-truncating mutations confer resistance to
chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells, Kahn et al.
study provides evidence that mutations of the serine-threonine phosphatase
gene PPM1D confer a selective growth advantage in the presence
of ongoing DNA damage. It further demonstrates that pharmacological targeting
of PPM1D can reverse this effect.
warfarin in high-risk patients with antiphospholipid syndrome, Pengo et al.
The investigators demonstrate that rivaroxaban is
inferior to warfarin for the prevention of thromboembolic events, major
bleeding, and vascular death in patients with high-risk antiphospholipid
antibody syndrome in a randomized, multicenter, controlled study
hematopoietic stem cells drive aging-associated immune remodeling, Leins et al.
These investigations show how much the decline of immune function
associated with aging is cell intrinsic and how much reflects declining thymic
function. In a series of studies in transgenic mice, they demonstrate that
functional aging primarily reflects hematopoietic stem cell aging and is
independent of thymic function.
the most cited peer-reviewed publication in the field of hematology, is
available weekly in print and online. Blood
is the flagship journal of the American Society of Hematology (ASH) (www.hematology.org),
the world’s largest professional society concerned with the causes and
treatment of blood disorders.
ASH’s mission is to
further the understanding, diagnosis, treatment, and prevention of disorders
affecting blood, bone marrow, and the immunologic, hemostatic, and vascular
systems by promoting research, clinical care, education, training, and advocacy
blood® is a registered
trademark of the American Society of Hematology.
back to top
Society of Hematology